# pcme Impact of Continuing Medical Education on the Recognition of Silent Atrial Fibrillation and Mitigation of Atrial Fibrillation-related Stroke Risk

Terry Ann Glauser, MD, MPH; Barry Watkins, PhD; Chad Williamson, MS, MBA, CMPP; Leanne Berger, BS; Thomas Sullivan; Potomac Center for Medical Education and Rockpointe, Columbia, MD

# Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia; however, approximately one third of people with AF are asymptomatic and remain undiagnosed.<sup>1,2</sup> To identify these individuals, guidelines recommend screening patients aged  $\geq$  65 years using pulse palpation, electrocardiogram (ECG), or hand-held devices.<sup>1,3-5</sup> Unfortunately, many primary care physicians (PCPs) are unaware of silent AF prevalence and few test for it.<sup>6,7</sup>

Once an individual is diagnosed with AF, guidelines recommend quantitating stroke risk using the CHA<sub>2</sub>DS<sub>2</sub>-VASc score, but PCPs often rely on clinical judgement alone.<sup>3,8-12</sup> Patients not assessed using CHA<sub>2</sub>DS<sub>2</sub>-VASc score are at risk of receiving guideline-discordant care, as evidence-based management depends on scoring results.<sup>10</sup> Many patients who should receive an anticoagulant are untreated, are not given the optimal evidence-based choice of oral anticoagulant (OAC), or do not receive the appropriate dose.<sup>13-18</sup>

Based on these knowledge and competence gaps, an educational intervention was developed to help PCPs recognize the need to screen for asymptomatic AF, use the CHA<sub>2</sub>DS<sub>2</sub>-VASc score to assess stroke risk, and improve their knowledge about OACs to individualize the management of their patients with AF.

# **Methods**

The objectives for the education were that participants would be able to:

- Identify patients who have high stroke-associated risk and undertake appropriate long-term monitoring
- Use the CHA<sub>2</sub>DS<sub>2</sub>-VASc risk assessment score as a tool to determine the appropriate course of action to manage diagnosed AF
- Consider appropriate oral anticoagulation for patients with newly diagnosed AF and high CHA<sub>2</sub>DS<sub>2</sub>-VASc risk score

The target audience was PCPs and other healthcare professionals who treat patients with stroke-associated risk factors and who may also have AF.

The program included 3 live activities in conjunction with chapter meetings of the American College of Physicians, 3 live activities at MEDX Regional Conferences, and an online enduring webcourse hosted on Primary Issues.

#### References

- 1. Mairesse GH et al. Europace. 2017;19:1589-1623. 2. Healey JS et al. Circulation. 2017;136:1276-1283.
- 3. Kirchhof P et al. *Eur Hear J*. 2016;37:2893-2862.
- 4. Meschia JF et al. Stroke. 2014;45:3754-3832.
- 5. Freedman B et al. Circulation. 2017;135:1851-1867.
- 6. Medscape Fast Five Quiz: Are you familiar with atrial
- fibrillation? March 2018.
- 7. The Economist Intelligence Unit. Preventing Stroke: Uneven Progress. 2017. 8. January CT et al. J Am Coll Cardiol. 2014;64:e1-e76
- 9. Lip GYH et al. Chest. 2018;154:1121-1201.
- 10. January CT et al. Circulation. 2019 Jan 29; Epub ahead of print.
- 11. Karcher R et al. Am J Med Qual. 2016;31:337-348.
  - 12. Glauser TA et al. Am J Med Qual. 2016;31:38-46.
  - 13. Mazurek M et al. Am J Med. 2017;130:135-145. 14. Steinberg BA et al. J Am Coll Cardiol. 2016:68:2597
  - 2604

15. Steinberg BA et al. Am Heart J. 2017:189:40-47. 16. Steinberg BS et al. J Am Heart Assoc. 2018;7:e00763. 17. Yao X et al. J Am Coll Cardiol. 2017:69:2779-2790. 18. Zhu J et al. *Pharmacotherapy*. 2018;38:907-920.

## **Participant Demographics**

	<b>ACP Meetings</b>	MEDX	Webcourse
Total learners	141	1,191	288
Total certificates	66	959	168
MD/DO	64 (97%)*	522 (44%) <sup>†</sup>	78 (46%)*
Other <sup>‡</sup>	2 (3%)*	669 (56%) <sup>†</sup>	90 (54%)*
MD/DO specialty			
Internal/Family Medicine	59 (92%)*	442 (85%) <sup>†</sup>	52 (67%)*
Other	5 (8%)*	80 (15%) <sup>†</sup>	26 (33%)*
Percentage of participants who see at least 6 patients per month with AF	71%	41%	33%

\*Based on certificates awarded <sup>†</sup>Based on all MD/DO <sup>‡</sup>Includes PharmD, NP, PA, RN, other

## **Evaluation of Activity**

#### **Live Activities**

Of the 1,125 participants who responded to the evaluation, 99% agreed that the activity provided strategies to improve their practice and better prepared them to care for their patients.

More than half of participants (58%) said at least half of the content was new to them.

#### Webcourse

Greater ability to assess and manage stroke risk in AF



Overall educational value of the activity

# Agreement that the activity will improve clinical care:



# Results

## **Knowledge and Competence**

The overall pre-test score was 63%, while the overall post-test score was 94%; P < 0.05

### **Overall Responses to Knowledge Questions**

Correct Response	Percent Correct on Pre-test	Percent Correct on Post-test	Absolute Increase Percentage	<i>P</i> value
$CHA_2DS_2$ -VASc risk score can be useful to identify people who have not been diagnosed with AF, but are at high risk for stroke (pre n= 966; post n = 1,031)	69%	98%	29%	< 0.05
Brief episodes (e.g. ~10 mins) of subclinical atrial tachyarrhythmias without clinical AF are associated with doubling the risk of stroke (pre n= 982; post n = 1,056)	58%	89%	31%	< 0.05
High-risk patients with newly diagnosed paroxysmal AF should be treated with oral anticoagulant therapy (pre n= 972; post n = 1,030)	63%	95%	32%	< 0.05

Percentage of respondents who were confident, very confident, or expert in managing patients who do not have a history of AF, but would be high stroke risk if they develop AF, increased from 36% (n = 915) before the activity to 81% (n = 1,227) after the activity; (P < 0.05).

## **Intent to Change Clinical Practice**



## **Barriers**

**ACP** meetings

After the activity, the issues perceived as high barriers to managing patients with undiagnosed/asymptomatic AF by the highest percentage of participants were:

- Unclear guidelines about management of high-risk patients with no evidence of AF (11%)
- Unclear guidelines about management of high-risk patients with history of AF (11%)
- Uncertainty about usefulness of patient-use AF detection technologies (10%)

## **MEDX** meetings

Uncertainty about the predictive value of patient-use devices for detection of AF (8%)

### Webcourse

# Discussion

The impact of the program was assessed by comparing pre- and post-activity scores. The difference between scores was expressed as % non-overlap, which correlates with effect size. Higher % non-overlap results indicate increased effectiveness of the education Using this assessment method, large effect sizes were observed in all three activities (ACP meetings, MEDX meetings, and webcourse) indicating a program that was very effective in educating clinicians.

Activity	% Non- overlap	
ACP	55.4	
MEDX	47.4	
Webcourse	47.4	

# Conclusion

- Statistically significant (P < 0.05) increase in knowledge about:
  - clinical AF
- Participants felt activity would improve patient care
- Participants were more confident in:

  - newly diagnosed AF
- Participants expressed intention to incorporate this information into practice
- Based on pre-test scores, there is a need for education on:
  - Using the CHA<sub>2</sub>DS<sub>2</sub>-VASc Risk Score
  - Individualizing oral anticoagulant therapy in patients with AF

(n=168)





• Uncertainty about the predictive value of patient-use devices for detection of AF (21%)

### **Practice Impact**

The 141 clinicians who participated in this activity are 55.4% more likely to deliver evidence-based care for AF, positively affecting the care of patients seen during 1,657 AF patient-visits each month.

The 1,191 clinicians who participated in this activity are 47.4% more likely to deliver evidence-based care for AF, positively affecting the care of patients seen during 8,706 AF patient-visits each month.

The 288 clinicians who participated in this activity are 47.4% more likely to deliver evidence-based care for AF, positively affecting the care of patients seen during 1,639 AF patient-visits each month.

• Before activity, 58% of participants were not familiar with at least half of the material

– Use of CHA<sub>2</sub>DS<sub>2</sub>-VASc to identify patients with high stroke risk not diagnosed with AF - Doubling of stroke risk with brief episodes of subclinical atrial tachyarrhythmia without

- Use of oral anticoagulant therapy in high-risk newly diagnosed paroxysmal AF

- Ability to identify patients at high risk of stroke using novel approaches - Using CHA<sub>2</sub>DS<sub>2</sub>-VASc to diagnose/manage AF and select oral anticoagulant therapy for

- Identifying patients at high risk for stroke who have not been diagnosed with AF